Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

42% of adults on Zepbound and 50% of adults on Zepbound with PAP therapy experienced remission or mild, non-symptomatic obstructive sleep apnea, compared to 16% and 14% of people who took the ...

“important risk factors for cardiovascular complications of obstructive sleep apnea with obesity,” researchers wrote in the ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Obstructive sleep apnea is when a person stops breathing five ... those with five to 15 disruptions, mild sleep problems; and those with more than 15, moderate to severe sleep problems.

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight ... which were typically mild to moderate, the researchers said ...